Navigation Links
Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Date:8/20/2008

l Market.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer.

Forward-Looking Statements

In order to provide our investors with an understanding of our current condition and future prospects, this release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements related to our ability to regain compliance with the listing standards of The NASDAQ Global Market or obtain listing on The NASDAQ Capital Market. Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the availability and adequacy of financing, our financial condition and results of operations, general economic factors, achievement of the results we anticipate from our clinical trials with our products and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Oncothyreon does no
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
2. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
3. Oncothyreon to receive milestone payment
4. Oncothyreon Reports First Quarter 2008 Financial Results
5. Oncothyreon files investigational new drug application for PX-866 oncology compound
6. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
7. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
8. Oncothyreon announces effectiveness of shelf registration statement
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon to present at upcoming investment conferences
11. Oncothyreon reports full year and fourth quarter 2007 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Milpitas, Calif. (PRWEB) , ... August 31, 2015 ... ... earlier this year to bring together supply chain risk management and resiliency practitioners ... collaborate, develop and share best practices, and be recognized for their innovations and ...
(Date:8/31/2015)... 31, 2015 MabVax Therapeutics Holdings, Inc. (OTCQB: ... the Company,s lead antibody, HuMab 5B1, will be garnering ... during the upcoming World Molecular Imaging Congress (WMIC) being ... 2015. Researchers from the Department of Radiology at Memorial ... the use of MabVax,s lead antibody as a PET ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Israel Biomedical Sensors Market - Growth, Trends & ... The Israel Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:8/31/2015)... TORONTO , Aug. 31, 2015 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), is pleased to announce that ... be advancing its lead candidate, PPL-003, to an Investigational ... dry eye disease and uveitis.  PPL recently completed a ... where topical PPL-003 solution achieved highly significant efficacy and ...
Breaking Biology Technology:Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3
... first-cycle,approval for a new molecular entity (NME) is ... average, according to a new analysis from,PAREXEL Consulting, ... PRXL ),and leading global life sciences consultancy serving ... PAREXEL Consulting,analysis, 60 percent of sales for newly-approved ...
... Medical and Security Detection Applications, ST. LOUIS, ... SAFC(R), a member of the Sigma-Aldrich Group (Nasdaq: ... the scope of its electronic materials,offering with the ... http://www.safchitech.com/halides ). These new raw materials enable the,growth ...
... ... Nutrition and Disease Research, KANNAPOLIS, N.C. ... Research Institute (DHMRI), located at the North,Carolina Research Campus ... that Waters(R) has been selected as the institute,s,primary supplier ...
Cached Biology Technology:PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 4PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 5SAFC Hitech(TM) Expands Electronic Materials Portfolio With the Introduction of Scintillation Crystal Growth Halides 2SAFC Hitech(TM) Expands Electronic Materials Portfolio With the Introduction of Scintillation Crystal Growth Halides 3SAFC Hitech(TM) Expands Electronic Materials Portfolio With the Introduction of Scintillation Crystal Growth Halides 4David H. Murdock Research Institute Taps Waters for Laboratory Technology 2David H. Murdock Research Institute Taps Waters for Laboratory Technology 3
(Date:8/5/2015)... 2015 According to a new ... Software, Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, ... Forecast to 2020", published by MarketsandMarkets, defines and segments ... various segments. The global PIAM Market is estimated to ... by 2019, at a CAGR of 14.9 % from ...
(Date:8/5/2015)... The biosensors market is proving highly attractive ... newer sectors, and development of devices resulting in higher ... seen the entry of multiple participants each year with ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) Recent ... Global Biosensors Market ( http://www.frost.com/nee9 ), finds that ...
(Date:8/4/2015)... Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today reported ... 2015. Highlights: , Second quarter contract revenue ... 2014 , Adjusted contract margins of ... $0.22, including a $0.05 decrease in EPS from royalties in the ... million "We are very pleased to present another ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... at the University of Leeds are developing methods of ... organic chemicals such as vinegar. , The harmful ... waste from former textiles factories, smelters, and tanneries have ... to problems with the kidneys, liver, lungs and skin. ...
... 3, 2009) When it comes to solving complex ... engineer, looks to nature for solutions. Finding inspiration in ... helping to tackle one of society,s biggest challenges: improving ... the survival rate of cancer patients. Today, ...
... March 2, 2009 Two researchers at UT ... Research Fellows, an award intended to "support the work ... and often at pivotal stages in their work." ... for their work in chemistry. The Alfred P. Sloan ...
Cached Biology News:Cleansing toxic waste -- with vinegar 2MIT student develops new innovations to selectively kill cancer cells 2MIT student develops new innovations to selectively kill cancer cells 3MIT student develops new innovations to selectively kill cancer cells 4Two UT Southwestern researchers awarded Sloan fellowships 2
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
... GenBank Accession Number : NM_201222 ... corresponding to amino acids 161-176 ... antiserum in 0.05% sodium azide ... routinely evaluated by immunoblot on ...
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Immunofixation Gel Kit, requires IF100 Reactivity: Human Applications: Immunofixation ...
Biology Products: